Glioblastomas are the most common and most aggressive brain tumors. Their survival rate has barely increased over the last 50 years, indicating an urgent need to develop new therapeutic strategies. In a paper published this week in the journal Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research, the team led by Massimo Squatrito, head of the Seve Ballesteros Foundation Brain Tumor Group at the Spanish National Cancer Research Center (CNIO), proposes a novel therapeutic strategy based on the combination of temozolomide, the first-line treatment for these patients, and dianhydrogalactitol, a drug that is being tested in clinical trials and is already approved for the treatment of other tumors.
